Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 7/20 | 0.45 |
| ▸ | REN | P00797 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PEPD | P12955 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151569 | 1.00 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1ACERENLMNA | |
| SCHEMBL151570 | 1.00 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1ACERENLMNA | |
| SCHEMBL593020 | 0.98 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1ACERENLMNA | |
| Hydrochloric Acid SCHEMBL9148101 | 0.98 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1ACERENLMNA | |
| Lithium SCHEMBL593022 | 0.98 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1ACERENLMNA | |
| Ammonia Solution, Strong SCHEMBL5017115 | 0.98 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1ACERENLMNA | |
| Hydrochloric Acid SCHEMBL9432225 | 0.98 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1ACERENLMNA | |
| SCHEMBL5434462 | 0.94 | SMN1; SMN2 (0.49) | ALDH1A1L3MBTL1ACERENLMNA | |
| SCHEMBL2158601 | 0.94 | SMN1; SMN2 (0.49) | ALDH1A1L3MBTL1ACERENLMNA | |
| SCHEMBL315372 | 0.94 | SMN1; SMN2 (0.49) | ALDH1A1L3MBTL1ACERENLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108660131-B | Preparation method of immobilized nitrile hydratase and (S) -N-ethylpyrrolidine-2-formamide | 浙江工业大学 | 2020-07-21 | — | — | CN | claimed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | claimed |
| WO-2006071079-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | claimed |
| EP-4301747-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. (CA) | 2024-01-10 | — | — | EP | disclosed |
| CN-117242065-A | Indole derivatives as serotonergic agents for the treatment of diseases associated therewith | 明德赛特制药公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023019366-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023006019-A1 | POLYSUBSTITUTED BENZENE PD-L1 INHIBITOR, COMPOSITION AND USE THEREOF | 杭州和正医药有限公司 | 2023-02-02 | — | — | WO | disclosed |
| WO-2022183288-A1 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2022-09-09 | — | — | WO | disclosed |
| CN-114615976-A | Kappa opioid receptor peptide amide agonists | 人福医药美国公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-108660131-B | Preparation method of immobilized nitrile hydratase and (S) -N-ethylpyrrolidine-2-formamide | 浙江工业大学 | 2020-07-21 | — | — | CN | disclosed |
| CN-104918615-B | The method for treating hepatopathy | 扎夫根股份有限公司 | 2018-10-12 | — | — | CN | disclosed |
| WO-2012154676-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-7989634-B2 | Melanocortin receptor agonists | LG LIFE SCIENCES LTD. (KR) | 2011-08-02 | — | — | US | disclosed |
| US-20110105511-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-20100137306-A1 | HETEROCYCLIC TRPV1 RECEPTOR LIGANDS | PURDUE PHARMA L.P. | 2010-06-03 | — | — | US | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
| US-20070015823-A1 | Ambruticin VS compounds | KOSAN BIOSCIENCES INCORPORATED | 2007-01-18 | — | — | US | disclosed |
| WO-2006071079-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | ALDH1A1 147/4885L3MBTL1 4240/4885ACE 763/4885 |
| US-20070015823-A1 | Ambruticin VS compounds | ERG28, O60361, CYP51A1 | ALDH1A1 4158/4885L3MBTL1 998/4885ACE 3636/4885 |
| US-20100137306-A1 | HETEROCYCLIC TRPV1 RECEPTOR LIGANDS | TRPV1, TRPA1, TRPV2 | ALDH1A1 566/4885L3MBTL1 4485/4885ACE 4382/4885 |
| US-20110105511-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | ALDH1A1 4540/4885L3MBTL1 2161/4885ACE 2493/4885 |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | LSS, ABCG2, SELL | ALDH1A1 533/4885L3MBTL1 1661/4885ACE 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.